Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical said that the patients receiving NX-1207 in Phase 3 trials recorded quantitative improvement in the symptom of urgent need to urinate.
Subscribe to our email newsletter
Nymox said that compared to baseline, symptoms of urgency to urinate reduced by 52% at 90 days after a single treatment with NX-1207, and the improvement was positive compared to double-blinded placebo control patients.
The study results showed that NX-1207 can better improve the signs and symptoms of BPH better that double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH.
Additionally in the trial, men treated with NX-1207 reported improvement in BPH symptoms 3 months after a single NX-1207 treatment.
In two multi-center Phase 2 US prospective randomised blinded clinical trials, the aggregated mean improvement in the BPH symptom score for 2.5mg NX-1207 was 10.3 points or a 44% improvement in BPH symptom score.